How much of your market can a single rule in another country reshape overnight?
Germany’s Federal Cabinet adopted a draft amendment to the Medizinal-Cannabisgesetz (MedCanG) that would ban purely remote prescriptions and the mail-order supply of medical cannabis, requiring in-person doctor contact instead. The proposal passed a first Bundestag reading in December 2025, but it has not advanced to the second and third readings required to become law, and it is not in force. For anyone watching the Germany medical cannabis market, the story is less about what changed and more about how quickly a destination country’s rulebook can shift.
What Did Germany Propose to Change?
On 8 October 2025, the Bundeskabinett adopted the Regierungsentwurf (government draft) amending the MedCanG. Under the proposal, cannabis could in future only be prescribed after in-person contact between doctor and patient, and treatment based exclusively on video consultation would be excluded for initial prescriptions. The draft would also prohibit the Versandhandel (mail-order trade) of medical cannabis for medical purposes, while pharmacy courier delivery (Botendienst) would remain available for patients with mobility limitations. Follow-up prescriptions could still be issued remotely only if the patient had an in-person consultation with the prescribing doctor within the previous four quarters.
The government’s stated rationale is to close the gap on online, questionnaire-only prescribing that operates with little medical oversight. Officials point to a surge in flower imports that far outpaced growth in statutory-insurance prescriptions, which they read as evidence of misuse through private prescriptions and telemedical platforms. If you are planning to operate in the country, our guide on how to get a cannabis licence in Germany covers the wider framework.
Why Has the Germany Medical Cannabis Reform Not Passed?
The bill was formally tabled and passed a first reading in the Bundestag on 18 December 2025, then was referred to the Gesundheitsausschuss (Health Committee). It has not since advanced to the second and third readings a bill needs to become law, so it is not in force. The draft has drawn criticism from legal experts and industry groups who question how workable the restrictions would be. The practical consequence is unchanged for now: telemedicine prescriptions and pharmacy mail-order supply of medical cannabis remain legal in Germany. The restrictions are proposed, not enacted.
Why This Matters Beyond Germany
The Germany medical cannabis market is the largest in Europe and a major import destination, which is why a domestic prescribing debate is a supply-chain story for producers everywhere. According to BfArM data, Germany imported 201,094 kg of medical cannabis flower in 2025, up roughly 176% on 2024. Canada was the single largest supplier at 93,006 kg, about 46% of the total, followed by Portugal at 55,164 kg. Much of that 2024 to 2025 boom was demand created by exactly the telemedicine and mail-order channel this amendment targets.
Germany’s top medical cannabis suppliers in 2025
| Supplier | Imported (2025) | Share of total |
|---|---|---|
| Canada | 93,006 kg | ~46% |
| Portugal | 55,164 kg | ~27% |
| All other origins | 52,924 kg | ~27% |
| Total imports | 201,094 kg | 100% |
If the reform passes, softer German demand would ripple straight back to exporters, and Canadian licensed producers would feel it most. That is the compliance lesson worth internalising: your biggest risks may not sit in your own jurisdiction at all. They can live in a destination country’s rulebook, where a single prescribing rule can reshape demand for product you have already cultivated and shipped.
How GrowerIQ Fits Into This
When a destination market changes its rules, the producers who adapt fastest are the ones whose records are already in order. GrowerIQ provides seed-to-sale traceability where data flows between cultivation, manufacturing, quality, and reporting without re-entry. That export-grade, audit-ready recordkeeping, aligned with frameworks like EU GMP, GACP and GPP, is what lets producers pivot quickly, redirect supply, and demonstrate compliance across borders when a market like Germany shifts. It is a general principle, not a claim about German prescribing law: clean traceability is the cheapest insurance against regulatory surprise.
Key Takeaways
- It is a proposal, not law: Germany’s Cabinet backed the MedCanG amendment on 8 October 2025, but after a first reading on 18 December 2025 it has not advanced and is not in force.
- What it would do: ban telemedicine-only prescriptions and mail-order (Versandhandel) supply of medical cannabis, requiring in-person doctor contact.
- Canada is most exposed: Canada supplied 93,006 kg (about 46%) of Germany’s 201,094 kg of 2025 imports, so a demand shift lands hardest on Canadian producers.
- The lesson: the Germany medical cannabis debate shows destination-market rules are a supply-chain risk; export-grade traceability is how producers stay ready to adapt.
Frequently Asked Questions
Is telemedicine prescribing of medical cannabis still legal in Germany?
Yes, for now. The amendment that would ban purely remote prescriptions and mail-order supply passed only a first Bundestag reading and is not in force, so telemedicine prescriptions and pharmacy mail-order supply remain legal in Germany.
What would the German MedCanG amendment change?
It would require in-person contact between doctor and patient for a medical cannabis prescription, exclude video-only initial prescriptions, and prohibit the mail-order (Versandhandel) supply of medical cannabis, while allowing pharmacy courier delivery for patients with mobility limitations.
Why does Germany’s medical cannabis reform matter for Canada?
Canada is Germany’s largest medical cannabis supplier, providing 93,006 kg (about 46%) of the 201,094 kg Germany imported in 2025. If the reform softens German demand, Canadian licensed producers would feel the impact most.
Last updated: July 2026
Ready to stay ahead of shifting export rules?
See how GrowerIQ gives licensed producers export-grade, audit-ready seed-to-sale visibility for markets like Germany.
REQUEST DEMO
Recommended For You
Germany’s Proposed Medical Cannabis Crackdown: What a Telemedicine and Mail-Order Ban Would Mean
July 20, 2026Six Nations Repeals Its Cannabis Control Law: A Lesson in Enforceable Regulation
July 17, 2026Brazil’s Cannabis New Era Begins: ANVISA’s RDC 1,015 Takes Effect and Reshapes Latin America’s Largest Medical Market
July 17, 2026About GrowerIQ
GrowerIQ is changing the way producers use software - transforming a regulatory requirement into a robust platform to learn, analyze, and improve performance.
To find out more about GrowerIQ and how we can help, fill out the form to the right, start a chat, or contact us.